新型5-HT4R激动剂PF-04995274与SSRI西酞普兰对未用药抑郁症情绪认知的早期效应:RESTAND研究
该双盲安慰剂对照试验将90例未用药重性抑郁障碍患者随机分配至7天PF-04995274(15 mg)、西酞普兰(20 mg)或安慰剂,评估情绪加工的行为与fMRI指标。西酞普兰降低负性面孔识别相对准确率并增加相对反应时,伴左侧杏仁核激活降低;PF-04995274未改变行为负性偏向或杏仁核活动,但增加内侧额叶皮层激活,且两种活性治疗均显示观察者评定抑郁严重度较安慰剂早期下降。
要点
- 西酞普兰7天即改变负性情绪偏向及杏仁核活动,PF-04995274无此典型抗抑郁认知特征。
- PF-04995274增加内侧额叶皮层激活,并伴自我报告抑郁、状态焦虑及负性情感早期改善。
- 结果提示5-HT4R激动剂可能通过不同于SSRI的通路产生抗抑郁效应,支持进一步临床试验。
核心结论
- PF-04995274未表现出西酞普兰典型的负性偏向降低特征,而是伴随内侧额叶激活增加及早期临床改善的初步证据,提示潜在替代抗抑郁通路。
研究设计与样本
- 双盲、安慰剂对照试验,90例未用药重性抑郁障碍患者随机接受7天PF-04995274(15 mg)、西酞普兰(20 mg)或安慰剂。
- 采用面部表情识别行为任务及内隐情绪面孔加工fMRI(第6-9天),并在基线与研究结束时评估观察者及自我报告抑郁症状。
- 临床试验注册号NCT03516604;原文注明该研究并非临床疗效试验。
主要发现
- 西酞普兰降低识别负性面孔的相对准确率并增加相对反应时,伴左侧杏仁核对面部情绪激活降低及皮层区域效价特异性变化。
- PF-04995274未改变行为负性偏向或杏仁核活动,但增加内侧额叶皮层跨效价激活。
- 两种活性治疗均显示观察者评定抑郁严重度较安慰剂早期下降;PF-04995274还降低自我报告抑郁、状态焦虑及负性情感。
关键数值与推荐
- PF-04995274剂量为15 mg、西酞普兰为20 mg,疗程均为7天。
- 情绪加工评估于第6-9天进行,样本量为90例重性抑郁障碍患者。
临床怎么用
- 结果为5-HT4R激动剂类抗抑郁药的早期情绪认知与神经标志物提供初步人体证据,尚不能用于临床处方决策。
- 西酞普兰7天内即可检测到负性偏向及杏仁核活动的改变,支持情绪认知任务作为早期靶点 engagment 指标。
- PF-04995274的内侧额叶激活增加与早期症状改善信号提示后续临床试验可关注促认知与心境效应。
局限性
- 原文明确该研究并非临床疗效试验,临床改善证据仅为初步性。
- 样本量90例、疗程仅7天,情绪加工评估集中于第6-9天,长期效应未知。
- 原文未报告效应量、置信区间或统计检验P值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) are limited by inadequate response in a significant proportion of patients, slow onset, minimal cognitive benefit and side-effects. Preclinical studies suggest selective serotonin 4 receptor (5-HT4R) agonists may produce faster antidepressant effects via distinct mechanisms; however, there has been no experimental research in clinical populations to date. AIMS: To test whether the novel 5-HT4R partial agonist PF-04995274 produces early behavioural and neural changes in emotional cognition similar to SSRIs in patients with unmedicated major depressive disorder (MDD). METHOD: In a double-blind, placebo-controlled trial, 90 participants with MDD were randomised to 7 days of PF-04995274 (15 mg), citalopram (20 mg) or placebo. Emotional processing was assessed using a behavioural facial expression recognition task and functional magnetic resonance imaging (fMRI) of implicit emotional face processing (days 6-9). Observer- and self-reported symptoms of depression were also measured at baseline and study end. RESULTS: As anticipated, citalopram reduced relative accuracy and increased relative reaction time to identify negative faces, with corresponding changes in neural activity (reduced left amygdala activation to emotional faces and valence-specific shifts in cortical regions). In contrast, PF-04995274 produced no change in behavioural negative bias or amygdala activity but increased medial-frontal cortex activation across valences. While this was not a clinical trial, both active treatments demonstrated an early treatment response with reduced observer-rated depression severity relative to placebo; PF-04995274 also reduced self-reported depression, state anxiety and negative affect. CONCLUSIONS: PF-04995274 did not show the typical antidepressant profile of negative bias reductions observed with citalopram. Instead, it was associated with distinct increased medial-frontal activation during an emotional faces task, coupled with preliminary evidence of early clinical improvement, suggesting a potential alternative pathway for antidepressant effects. Findings support further clinical trials of 5-HT4R agonists and investigation of pro-cognitive and mood effects. CLINICAL TRIALS REGISTRATION NUMBER: NCT03516604.
引用
- Gillespie AL, de Cates AN, Scaife J, et al. Early effects of a novel 5-HT4R agonist (PF-04995274) and the SSRI citalopram on emotional cognition in unmedicated depression: RESTAND study. Br J Psychiatry. 2026. PMID: 42204761. doi:10.1192/bjp.2026.10664
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。